Clinical trials: Philadelphia Chromosome-Negative Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01366898
- Testing
- Dexamethasona, Idarubicine, ARA-C, Methotrexate
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
This is the study to test combination regimen of Nilotinib and Ruxolitinib therapy for the treatment of patients with Philadelphia positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who is resistant to…
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT01914484
- Testing
- Nilotinib, Ruxolitinib
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Acute Lymphoblastic Leukemia
CAV Regimen for R/R Ph- B-ALL
This study aims to investigate the efficacy and safety of cladribine, venetoclax combined with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia Chromosome-negative (Ph-) B-cell acute…
- Trial name
- NCT05657652
- Testing
- cladribine, cytarabine,venetoclax
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL.
- Trial name
- NCT06481228
- Testing
- CAR-T cells, Venetoclax, Olverembatinib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ALL
A Multicenter Study of CAR-T Cells in Primary Ph+All
A Multicenter Study of CD19 CAR-T Cells in the Treatment of Adult Patients With Primary Ph Chromosome Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT07252336
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to assess the safety and efficacy of ponatinib in Japanese patients with chronic myeloid leukemia (CML) who have experienced failure of dasatinib or nilotinib or with Ph+ acute lymphoblastic leukemia…
- Trial name
- NCT01667133
- Testing
- ponatinib - Phase 1, ponatinib - Phase 2
- Where
- 11 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ariad Pharmaceuticals
B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this research study is to determine the acceptable upper limit dose of nivolumab in combination with dasatinib that may be given to patients with relapsed/refractory philadelphia chromosome positive acute…
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02819804
- Testing
- Dasatinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Leukemia, Leukemia, Acute
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this…
- Conditions
- Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell
- Trial name
- NCT03564470
- Testing
- Chidamide, Dasatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lymphoblastic Leukemia, Philadelphia-Positive ALL
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
The goal of this prospective, multicenter, open observational study is to assess the efficacy and safety of the treatment for acute lymphoblastic leukemia Ph' positive adult patients with approved combinations of chemotherapy and…
- Conditions
- Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL
- Trial name
- LALPh2022 (NCT06175702)
- Testing
- Vincristine, Dexamethasone, Imatinib
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2…
- Trial name
- CAMS-Ph+ B-ALL (NCT07152041)
- Testing
- olverembatinib
- Where
- 24 sites in China, Hong Kong
- Volunteers
- 150 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL
Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
This is a phase II interventional trial to evaluate the efficacy of blinatumomab followed by high-dose chemotherapy in the first-line treatment for Ph-negative acute lymphoblastic leukemia (ALL) in adults.
- Conditions
- Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed
- Trial name
- Blina-CELL (NCT04554485)
- Testing
- Blinatumomab
- Where
- 5 sites in Czechia
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor.
- Trial name
- NCT04375683
- Testing
- Flumatinib
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Zhongda Hospital
Leukemia, Acute Lymphoblastic
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
Previous work performed by University of New Mexico Comprehensive Cancer Center (UNMCCC) investigators has revealed previously unknown genomic mutations in children, adolescents, and young adults with high-risk B and T cell…
- Trial name
- NCT02580981
- Testing
- Acute Lymphobastic Leukemia (ALL) Treatment Options
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- New Mexico Cancer Research Alliance
Acute Lymphoblastic Leukemia
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia
Metformin's Antitumor activity were identified from differens diabetic patients trials, mainly associated to its mechanism of action and protein - kinase AMPK (AMP-activated protein kinase) activation.
- Trial name
- NCT03118128
- Testing
- Metformin
- Volunteers
- 102 people
- Sponsor
- Hospital General de Mexico
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03263572
- Testing
- Blinatumomab, Cytarabine, Methotrexate
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphocytic, Acute, Adult
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed…
- Trial name
- NCT06649422
- Testing
- Blinatumomab
- Volunteers
- 36 people
- Sponsor
- Shandong University
ph+ Acute Lymphoblastic Leukemia
Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
The aim of our study is to improve the major molecular remission(MMR) rate and reduce the cost to treat ph(+) Acute Lymphoblastic Leukemia (ALL) by adjusting chemotherapy regimens and the dosage of Tyrosine Kinase Inhibitor…
- Trial name
- TCLDCWTTNDPP (NCT02690922)
- Testing
- Dasatinib, prednisone, dexamethasone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.
- Trial name
- LAL2317 (NCT03367299)
- Testing
- Chemotherapy + Blinatumomab
- Where
- 62 sites in Italy
- Volunteers
- 149 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Current therapeutic protocols for adult ALL consider MRD together with the baseline risk factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for treatment decisions.
- Trial name
- LAL-AR/2003 (NCT00853008)
- Testing
- Vincristine, Daunorubicin, Prednisone
- Where
- 38 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation